Boston Scientific Logo

CONTAK RENEWAL 3 RF

The CONTAK RENEWAL® 3 RF and CONTAK RENEWAL 3 RF HE cardiac resynchronization therapy defibrillators (CRT-Ds) provide ventricular tachyarrhythmia therapy and cardiac resynchronization therapy (CRT) and features telemetry communication with ZIP™ wandless telemetry.
 Contact Us About This Product
HEALTH CARE PROFESSIONALS
Overview

Key Features

ZIP Wandless Telemetry

Enables wireless communication between the pulse generator and the programmer

  • Eliminates the need for the wand in the sterile field, which may reduce the risk of infection
  • Enables you to continue the implant procedure while the device is optimally programmed for your patient
  • Provides faster data transmission speed, which means less time is required for device interrogation

Enables use of the LATITUDE® Patient Management system in the home

  • Enables LATITUDE Active Monitoring - delivers confidence and assurance by performing a device check every day for the life of the device
  • Allows automatic scheduled interrogations - makes device follow-up easy for patients and convenient for practices

Independent Channels

Independently programmable right ventricular (RV) and left ventricular ( LV ) pacing and sensing

  • RV sensing is only used for tachyarrhythmia detection and RV pacing inhibition
  • LV sensing is only used for LV pacing inhibition

High Energy Models

  • High-energy models H217 (IS-1) and H219 (LV-1) offer 41 J stored energy.

Ventricular Rate Regulation (VRR)

Designed to reduce irregular ventricular intervals during conducted atrial arrhythmias

  • Maximizes CRT delivery when programmed to the Maximum setting
  • Only active during mode switch in tracking modes
  • Available continuously in VVI(R) and DDI(R) modes
  • Programmable: Off, Minimum, Medium, Maximum

Atrial Fibrillation (AF) in Heart Failure (HF) Patients

  • The prevalence of AF increases as the severity of HF increases. 1
  • The incidence of AF in HF ranges from 10% to 50%. The highest incidence is in those with severe HF. 2
  • Patients with AF and severe HF experience a reduction in stroke volume, cardiac output and peak oxygen consumption. 1
  • These patients have a reduction of approximately 20% in cardiac output. 1

IS-1 or LV-1 Left Ventricular Pace/Sense Lead Port

  • Models H210 and H217 HE offer an IS-1 left ventricular pace/sense lead port
  • Models H215 and H219 HE offer an LV-1 left ventricular pace/sense lead port

Left Ventricular Protection Period (LVPP)

Prevents pacing during the left ventricular vulnerable period (T-wave)

  • LVPP is the period after a left ventricular event, either paced or sensed, when LV pacing is inhibited
  • Programmable:  300-500 ms

Tracking Preference

Designed to maintain atrial-tracked ventricular pacing in DDD(R) and VDD(R) modes

  • Temporarily reduces PVARP to reestablish atrial-tracked ventricular pacing inappropriately lost due to atrial events occurring in PVARP
  • Programmable:  On, Off
  1. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiciology, and rationale for therapy. Am J Cardiol. 2003;91(suppl):2D-8D.
  2. The AF-CHF Trial Investigators. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J. 2002;144:597-607.


Patient-centric Diagnostics

Autonomic Balance Monitor

ABM is a device calculation based on R-R interval measurements and mathematically functions as a surrogate measurement for LF/HF ratio.

  • LF/HF is considered a measure of sympathovagal balance and sympathetic modulations 1

HRV Monitor Footprint

Measures changes in intrinsic heart rate and plots the distribution of variability versus heart rate over a 24-hour period

  • Displays current footprint and one previously stored footprint to allow for comparison
  • Heart rate is plotted on the X axis, variability is plotted on the Y axis, and frequency is plotted using color
  • Shows a percentage for the total plot area covered by the footprint
  • Vertical line indicates mean heart rate
  • Increases in plot area indicate increases in heart rate variability (HRV) and/or heart rate range

HRV Monitor Trending

Plots heart rate (mean, minimum and maximum), HRV Monitor Footprint percentages, SDANN and ABM daily for 30 days and weekly for a 28 weeks

Activity Log

Plots the percent of day active for every day of the last 30 days and every week of the last 28 weeks I

  • Percent of day active is the percent of day the accelerometer-indicated motion is above a fixed minimal threshold

 

  1. ACC/AHA guidelines for ambulatory electrocardiography. J Am Coll Cardiol. 1999;34:912-48.

Mechanical Specifications

Model

Type

Size (cm) (H x W x D)

Mass (g)

Volume (cc)

Defibrillating Lead Ports

Atrial and Right Ventricular Pace/Sense Lead Ports

Left Ventricular Pace/Sense Lead Port

H210

DR

7.78 x 6.24 x 1.40

82

39

DF-1

IS-1

IS-1

H215

DR

7.78 x 6.24 x 1.40

82

39

DF-1

IS-1

LV-1

H217 (HE)

DR

8.26 x 6.60 x 1.40

90

43

DF-1

IS-1

IS-1

H219 (HE)

DR

8.26 x 6.60 x 1.40

90

43

DF-1

IS-1

LV-1



Image Gallery
Activity Log Autonomic Balance Monitor HRV Monitor Footprint HRV Monitor Trending

Product Type

Cardiac Resynchronization Therapy

Used in Procedures

Cardiac Resynchronization Therapy Implantation

Related Medical Areas

Cardiac Rhythm Management

Related Conditions

Heart Conditions

Related Products

ACUITY™ Spiral LV Lead ACUITY™ Steerable IS-1 LV Lead COGNIS™ Cardiac Resynchronization Therapy Defibrillator (CRT-D) CONTAK RENEWAL TR EASYTRAK® Left Ventricular Pacing/Sensing Leads ENDOTAK RELIANCE® G Defibrillation Lead LIVIAN™ Cardiac Resynchronization Therapy Defibrillator